Erschienen in:
01.09.2013 | Original Article
Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer
verfasst von:
Masanori Kobayashi, Tomoyo Sakabe, Hirofumi Abe, Mitsugu Tanii, Hidenori Takahashi, Asako Chiba, Eri Yanagida, Yuta Shibamoto, Masahiro Ogasawara, Shun-ichi Tsujitani, Shigeo Koido, Kazuhiro Nagai, Shigetaka Shimodaira, Masato Okamoto, Yoshikazu Yonemitsu, Noboru Suzuki, Masaki Nagaya, The DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT)
Erschienen in:
Journal of Gastrointestinal Surgery
|
Ausgabe 9/2013
Einloggen, um Zugang zu erhalten
Abstract
Background
The aim of this retrospective study was to clarify the safety and efficacy of dendritic cell (DC)-based immunotherapy targeting synthesized peptides, Wilms tumor 1 (WT1) and Mucin 1, cell surface associated (MUC1) for biliary tract cancers (BTCs).
Methods
Sixty-five patients who had nonresectable, recurrent, or metastatic BTCs and received the DC-based immunotherapy were selected for the study. DCs were pulsed with WT1 and/or MUC1. The adverse events (AEs) and clinical responses were examined.
Results
No serious treatment-related AEs were observed. Median survival time (MST) from diagnosis and from the first vaccination was 18.5 and 7.2 months, respectively. By multivariate Cox proportional hazard analysis, the significant independent factors were found to be (1) combined chemotherapy, (2) albumin level ≥4.0 g/dL before vaccination, (3) C-reactive protein level <0.5 mg/dL before vaccination, and (4) fever after vaccination. The MST from the first vaccination with or without chemotherapy was 8.2 and 5.3 months, respectively (P = 0.016), and MST for the patients with prognostic nutritional index ≥40 and <40 was 8.1 and 5.0 months, respectively (P = 0.023).
Conclusions
Although a small uncontrolled nonrandomized study, DC-based immunotherapy for BTCs was safe and produced a clinical response for the patients who underwent chemotherapy and maintained a good nutrition status.